Models for predicting hepatitis B e antigen seroconversion in response to interferon-α in chronic hepatitis B patients

Table 2 Factors at baseline influencing hepatitis B e antigen seroconversion in treated patients evaluated using univariate and multivariate analyses n (%)

Parameter	RS	Univariate analysis	P value	Multivariate analysis	P value
		OR (95%CI)		OR (95%CI)
Female gender	14 (34.1)	1.15 (0.53-2.47)	0.725
Age > 24 yr	26 (40.0)	1.94 (0.96-3.91)	0.065
ALT > 4 × ULN	33 (44.6)	3.39 (1.62-7.12)	0.001	2.44 (1.10-5.42)	0.028
HBV DNA ≤ 7
log10 copies/mL	22 (39.3)	1.71 (0.84-3.46)	0.138
HBsAg ≤ 15000 IU/mL	27 (40.3)	2.03 (1.00-4.09)	0.049
HBeAg ≤ 500 S/CO	26 (47.3)	3.03 (1.48-6.22)	0.003	2.12 (0.97-4.64)	0.060
anti-HBc > 11.4 S/CO	33 (45.8)	3.69 (1.75-7.75)	0.001	3.02 (1.39-6.57)	0.005
Genotype B	26 (30.6)	0.91 (0.50-1.65)	0.749

ALT: Alanine aminotransferase; ULN: Upper limit of normal; HBV: Hepatitis B virus; HBsAg: hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; anti-HBc: Antibody to hepatitis B core antigen; RS: Patients with HBeAg seroconversion.